Article
Interferon-free regimens for hepatitis C: combine and conquer.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy - 1 Apr 2014
Martel-Laferrière Valérie, Bichoupan Kian, Dieterich Douglas T
Abstract excerpt
Since the approval of the first direct-acting antiviral agents (DAAs), treatment for hepatitis C virus (HCV) has undergone significant transformation. A new milestone in the treatment of HCV, the approval of the first interferon-free regimens, could be achieved by the end of 2013. For patients with HCV who have absolute or relative contraindications to pegylated-interferon or have failed the currently available...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.